160 likes | 286 Vues
EU Research and Patient Safety. UK Presidency Workshop on Patient Safety, EHFG, Bad Hofgastein,7 September 2005. Kevin McCarthy, European Commission Health Research Directorate, DG Research,. Patient Safety Research & Europe. Factors influencing such research in the European context:.
E N D
EU Research andPatient Safety UK Presidency Workshop on Patient Safety, EHFG, Bad Hofgastein,7 September 2005 Kevin McCarthy, European CommissionHealth Research Directorate, DG Research,
Patient SafetyResearch & Europe Factors influencing such research in the European context: Deliberations at the European level - HLG Research support to operational / policy services FP6 - Scientific Support to Policy emphasis on patient mobility and quality issues: SSP projects: E4P & MARQUIS … Experience from current and completed projects – Internal Market (4FP), REBEQI, QM in Health (5FP) Deliberations at the international & regional levels – World Alliance, WHO/EURO work The next FP …
Patient SafetyResearch & Europe A pan-European approach : Europe is a natural laboratory Critical mass on best practice Health policy-driven research allows comparisons of national models & data Experience at the international level
The Patient & FP7(2007-2013) • Health • Food, agriculture and biotechnology • Information and communication technologies • Nanosciences, nanotechnologies, materials and new production technologies • Environment (including climate change) • Socio-economic sciences and the humanities
Health Research Theme • Under each theme there will be sufficient flexibility to address both Emerging needs and Unforeseen policy needs • Dissemination of knowledge and transfer of results will be supported in all thematic areas • Support will be implemented across all themes through: Collaborative research (Collaborative projects; Networks of Excellence; Coordination/support actions) Joint Technology Initiatives Coordination of non-Community research programmes (ERA-NET; ERA-NET+; Article 169) International Cooperation
HEALTH THEME - COLLABORATIVE RESEARCH Objective: Improving the health of European citizens Increasing the competitiveness of European health-related industries and businesses Addressing global health issues including emerging epidemics
FP7 HEALTH RESEARCH Activities 3 Pillars Biotechnology, generic tools and technologies for human health Translating research for human health Optimising the delivery of health care to European citizens
FP7 & PATIENT SAFETY Third Pillar: Optimising the delivery of health care to European citizens Enhanced health promotion and disease prevention Translating clinical research into clinical practice Quality, solidarity and sustainability of heath systems
FP7 & PATIENT SAFETY I. Enhanced health promotion & disease prevention: Provide evidence for the best public health measures in terms of life styles and interventions - different levels & different contexts Focus on the wider determinants of health and how they interact at both the individual and community level: For example diet, stress, tobacco and other substances, physical activity, cultural context, socio-economic and environmental factors. Mental health to be addressed in a life-course perspective
FP7 & PATIENT SAFETY II.Translating clinical research into clinical practice: Better use of medicines, and appropriate use of behavioural and organisational interventions and health therapies and technologies Special attention paid to patient safety: to identify the best clinical practice to understand decision making in clinical settings in primary and specialised care to foster applications of evidence-based medicine and patient empowerment Focus the benchmarking of strategies; investigating outcomes of different interventions including medicines, taking into consideration pharmacovigilance evidence, specificities of the patient (e.g. genetic susceptibility, age, gender and adherence) and cost benefits
FP7 & PATIENT SAFETY III. Quality, Solidarity and sustainability of health systems: Basis for countries to adapt their health systems National contexts and population characteristics taken into account Organisational, financial and regulatory aspects Implementation Outcomes - effectiveness, efficiency and equity Special attention on investment issues and human resources
Innovative Medicines Joint Technology Initiative Long term objective: To increase the competitiveness of the European Pharmaceutical industry, and to foster Europe as the most attractive place for pharmaceutical R&D. Thereby enhancing access of innovative medicines to the benefit of patients and society. Aim: To remove major bottlenecks in the drug development process, as identified by industry, and where research is the key.
Innovative Medicines Initiative • Industry (under the leadership of EFPIA) has identified the bottlenecks in agreement with key stakeholders: academia, regulatory agencies, patient organisations, clinical researchers, ethical experts, etc. • A Strategic Research Agenda prioritising the research needs and how they should be implemented has been developed by panels of experts: • Prediction of safety • Earlier indication of efficacy • Knowledge management • Education & training
Potential areas:Patient Safety Research (i): • Domains identified by the HLG: • Financial costs and benefits of implementing improved systems – inter-relationships, economic analysis • Contribution to design for safety – SMEs are innovative • Networking – ERA-Net tool • New knowledge and better understanding e.g. magnitude and quality of adverse events outside the hospital setting • Engaging with the patient, with society – communication • Links to international and regional developments – World Alliance, WHO
Potential areas:Patient Safety Research (ii): • Major scientific conference and public health intervention research – a 6th FP SSP initiative: 5th Call • FP7 - A health systems approach with appropriate methodologies being developed: • epidemiology of adverse events - identification, measurement, frequency, causes, determinants, and impact on patient outcomes • effective methods for preventing such events; • optimizing patient safety, best practice • Evidence-based medicine • Contributions from IT, nanotechnologies
Information • EU research: http://europa.eu.int/comm/research • Seventh Framework Programme: http://europa.eu.int/comm/research/future/index_en.cfm • Information on research programmes and projects: http://www.cordis.lu • RTD info magazine: http://europa.eu.int/comm/research/rtdinfo/ • Information requests:research@cec.eu.int